UBS Group Reiterates €184.00 Price Target for Sartorius (FRA:SRT3)
UBS Group set a €184.00 ($213.95) price objective on Sartorius (FRA:SRT3) in a research note released on Friday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
SRT3 has been the topic of a number of other research reports. Hauck & Aufhaeuser set a €55.00 ($63.95) price target on Cancom and gave the company a buy rating in a research note on Thursday, April 4th. Deutsche Bank increased their price target on Bed Bath & Beyond from $15.00 to $19.00 and gave the company a hold rating in a research note on Thursday, April 11th. Nord/LB set a €115.00 ($133.72) price target on Sartorius and gave the company a sell rating in a research note on Tuesday, April 23rd. Warburg Research set a €17.00 ($19.77) price target on Leoni and gave the company a neutral rating in a research note on Wednesday, May 15th. Finally, HSBC set a €150.00 ($174.42) price target on Sartorius and gave the company a neutral rating in a research note on Friday, July 12th. Five research analysts have rated the stock with a sell rating and four have given a hold rating to the company’s stock. The company has a consensus rating of Sell and an average target price of €137.94 ($160.40).
SRT3 opened at €191.30 ($222.44) on Friday. Sartorius has a 1-year low of €71.00 ($82.56) and a 1-year high of €124.70 ($145.00). The firm has a fifty day simple moving average of €179.52.
Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.
Recommended Story: Institutional Investors
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.